Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2021 Results and Provides Business Update
– Regained North American Rights to Vyleesi® for HSDD with Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March 31, 2021 – Phase 2 Clinical Results of PL9643 for the Treatment of Dry Eye Disease on Track for December 2020 – $86.6 Million in Cash and Cash Equivalents as of September 30, 2020 …